SOVATOP

Pantoprazole-based acid suppression therapy for the treatment of acid-related gastrointestinal conditions.

Gastrointestinal

SOVATOP

SOVATOP contains pantoprazole and is available as tablets and parenteral formulations for the treatment of acid-related gastrointestinal conditions.

SOVATOP packshot 1
SOVATOP packshot 2

Therapeutic Category

Proton Pump Inhibitors

Available Strengths

40mg

Dosage Form

Tablets & Parenteral

Pack size

Pack of 1x10ml , 3x10mg

Therapeutic Indications

  • Reflux oesophagitis
  • Gastric and duodenal ulcer
  • Zollinger – Ellison Syndrome and other pathological hypersecretory conditions.
SOVATOP 40 INJECTION packshot

Brand Name

SOVATOP

Product Name

SOVATOP 40 INJECTION

Generic Name

Pantoprazole for Injection BP 40 mg

Dosage Form

Parenteral

Pack Size

Combipack of 1 Vial packed with a 10 ml ampoule of Sodium Chloride as the diluent.

SOVATOP 40 INJECTION

Pantoprazole for Injection BP 40 mg

View Product Information
QR code for SOVATOP 40 INJECTION patient information leaflet

Scan for PIL

Therapeutic Indication

Provides effective management of acid-related condition by reducing excessive gastric acid secretion, relieving symptoms, and promoting healing in reflux oesophagitis, peptic ulcers, and hypersecretory conditions.

Dosage and Method of Administration

Adult:

  • Gastric & duodenal ulcer, reflux oesophagitis: 40 mg intravenously once daily.
  • Zollinger–Ellison syndrome & pathological hypersecretory conditions: Starting dose of 80 mg/day intravenously, the dose should be divided and given twice daily.

Special population:

  • Hepatic impairment: Maximum recommended dose is 20 mg/day in patients with severe liver impairment.

Mode of Administration

  • For I.V use only.
SOVATOP 40 TABLETS packshot

Brand Name

SOVATOP

Product Name

SOVATOP 40 TABLETS

Generic Name

Pantoprazole Sodium Delayed Release Tablet 40mg

Dosage Form

Tablets

Pack Size

Pack of 3x10mg

SOVATOP 40 TABLETS

Pantoprazole Sodium Delayed Release Tablet 40mg

Therapeutic Indication

Provides effective management of acid-related condition by reducing excessive gastric acid secretion, relieving symptoms, and promoting healing in reflux oesophagitis, peptic ulcers, and hypersecretory conditions.

Dosage and Method of Administration

Adults:

  • Reflux oesophagitis, gastric and duodenal ulcers, NSAID-associated ulcers:40 mg once daily.
  • Maintenance therapy for reflux oesophagitis:40 mg once daily.
  • Helicobacter pylori eradication:40 mg twice daily
  • Zollinger–Ellison syndrome and other pathological hypersecretory conditions:2 tablets of 40 mg daily.

Mode of Administration

Only for oral use.